Figure 2. Two-way sensitivity analysis strategy graph comparing risk reduction and adherence for isoniazid/rifapentine daily for one month (1HP).

The clear area shows combinations of adherence and risk reduction for 1HP that are high enough that 1HP is a cost-saving regimen. In the cross-hatched area, all combinations of adherence and risk reduction for 1HP are too low, so isoniazid/rifapentine monthly for 12 weeks self-administered (3HP-SAT) is preferred regimen.